Intellia Therapeutics (NTLA)
12.74
0.00 (0.00%)
Upcoming Events
Latest Headlines
FDA accepts Intellia's lonvo-z application with priority review status
September 8, 2026 8:10 AM - StreetInsider
Intellia Therapeutics (NTLA) Reiterated at Market Outperform by Citizens on HAE Opportunity
September 8, 2026 4:25 AM - StreetInsider
Intellia Therapeutics (NTLA) Reiterated at Market Outperform by Citizens Before ESC Congress
August 25, 2026 4:14 AM - StreetInsider
Form 4 Intellia Therapeutics, For: Aug 20 Filed by: LEONARD JOHN M
August 24, 2026 4:05 PM - SEC Filing
Form 144 Intellia Therapeutics, Filed by: LEONARD JOHN M
August 20, 2026 4:04 PM - SEC Filing
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 7, 2026 4:01 PM - Globe NewsWire
Form SCHEDULE 13G Intellia Therapeutics, Filed by: STATE STREET CORP
August 7, 2026 9:55 AM - SEC Filing
Evercore ISI Upgrades Intellia Therapeutics (NTLA) to Outperform
August 6, 2026 4:17 PM - StreetInsider
Form 10-Q Intellia Therapeutics, For: Jun 30
August 6, 2026 4:08 PM - SEC Filing
Intellia Therapeutics (NTLA) PT Lowered to $49 at Jefferies
August 6, 2026 12:55 PM - StreetInsider
Form 8-K Intellia Therapeutics, For: Aug 06
August 6, 2026 7:45 AM - SEC Filing
Intellia Therapeutics (NTLA) Reports In-Line Q2 EPS
August 6, 2026 7:24 AM - StreetInsider
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
August 6, 2026 7:00 AM - Globe NewsWire
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
July 30, 2026 8:00 AM - Globe NewsWire
Form 4 Intellia Therapeutics, For: Jul 22 Filed by: Dulac Edward J III
July 24, 2026 5:26 PM - SEC Filing
Wolfe Research Downgrades Intellia Therapeutics (NTLA) to Underperform
July 16, 2026 2:21 AM - StreetInsider
Form 4 Intellia Therapeutics, For: Jul 01 Filed by: Dube Michael P
July 6, 2026 5:02 PM - SEC Filing
Form 4 Intellia Therapeutics, For: Jul 02 Filed by: Dulac Edward J III
July 6, 2026 5:01 PM - SEC Filing
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 6, 2026 4:05 PM - Globe NewsWire
Form 144 Intellia Therapeutics, Filed by: Dulac Edward J III
July 2, 2026 4:34 PM - SEC Filing
Canaccord Reiterates Buy Rating on Intellia Therapeutics (NTLA)
June 16, 2026 6:37 AM - StreetInsider
Form 8-K Intellia Therapeutics, For: Jun 13
June 15, 2026 8:52 AM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Intellia Therapeutics (NTLA)
June 15, 2026 6:48 AM - StreetInsider
Intellia Therapeutics (NTLA) Reiterated at Market Outperform by Citizens
June 15, 2026 5:41 AM - StreetInsider
Intellia reports positive Phase 3 results for hereditary angioedema treatment
June 13, 2026 7:30 AM - StreetInsider
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
June 13, 2026 7:30 AM - Globe NewsWire
Form 4 Intellia Therapeutics, For: Jun 09 Filed by: Verwiel Frank
June 10, 2026 7:08 PM - SEC Filing
Form 4 Intellia Therapeutics, For: Jun 09 Filed by: Keresty Georgia
June 10, 2026 7:07 PM - SEC Filing
Form 4 Intellia Therapeutics, For: Jun 09 Filed by: GOODMAN JESSE
June 10, 2026 7:06 PM - SEC Filing
Form 4 Intellia Therapeutics, For: Jun 09 Filed by: Goff Brian
June 10, 2026 7:03 PM - SEC Filing
Form 4 Intellia Therapeutics, For: Jun 09 Filed by: Cohen Fred E
June 10, 2026 7:02 PM - SEC Filing
Form 4 Intellia Therapeutics, For: Jun 09 Filed by: CHASE WILLIAM J
June 10, 2026 7:01 PM - SEC Filing
Form 4 Intellia Therapeutics, For: Jun 09 Filed by: Bhanji Muna
June 10, 2026 6:58 PM - SEC Filing
Form 8-K Intellia Therapeutics, For: Jun 09
June 10, 2026 4:36 PM - SEC Filing
Full Article List
